Stocks and Finance

Pozen

Pozen 4/27/2012

07:45 : Pozen (POZN) -24.7% premarket after the biotech company discloses the ... - Pozen (POZN) -24.7% premarket after the biotech company discloses the FDA requested additional data for its PA32540 fixed-dose "safer aspirin" product which may delay submission of its new drug application. Post your comment!
Source : seekingalpha-com

Pozen 3/23/2012

04:18 : Drug maker Pozen announces positive results for its aspirin - Chapel Hill company hopes to find a marketing partner for drug by the end of the year. Company projects drug could have peak U.S. sales of $400 million.Click to Continue »
Source : newsobserver-com

Pozen 3/22/2012

10:38 : Pozen shares rise on upbeat test results - Pozen shares jumped as much as 19 percent this morning after the Chapel Hill company announced positive test results for the specialty aspirin it is developing.Click to Continue »
Source : newsobserver-com

Pozen 11/25/2011

14:30 : Pozen stock jumps after future royalty payments sold for $75 million - Chapel Hill drug company Pozen's stock is up 40 percent in early trading today on news that the company has sold the U.S. royalty payment rights to one of its drugs for $75 million.
Source : newsobserver-com
10:01 : Drug developer Pozen ([[POZN]] +40%) soars after reporting late Wednesday - Drug developer Pozen (POZN +40%) soars after reporting late Wednesday that it sold the U.S. royalty rights from its migraine drug Treximet to Canada's national pension fund, CPPIB Credit Investments. Post your comment!
Source : seekingalpha-com

Pozen 10/4/2011

10:51 : Pozen adjusts financial guidance - Pozen Inc. has adjusted its financial guidance for the year and now expects to generate $18 million to $19 million in revenue for 2011 as a result of favorable patent rulings. The Chapel Hill-based drug company had won favorable verdicts ...
Source : bizjournals-com
actualidad Pozen -

Pozen by date


Pharmaceuticals

Medical Supplies

Medical Equipment

Health Care Providers

Biotechnology

Copyright © 2009 Finaperf.com - Exchange rate - Investir - Stock Exchange - Börse - Finanças - Bolsa - Tous droits réservés
Site édité par Yanga.net - Contacts